Castration-Resistant Prostate Cancer HRPCA Therapeutics Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Castration-Resistant Prostate Cancer HRPCA Therapeutics Market to 2027 - Global Analysis and Forecasts by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiotherapy); Drug Delivery (Oral, Injectable.)

Report Code: TIPRE00004606 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Castration-Resistant Prostate Cancer/HRPCA is a type of prostate cancer that recurs after administration of androgen deprived therapy. It is defined by diseases progression and may also present as either continuous rise in serum prostate-specific antigen levels, or appearance of new metastases.

MARKET DYNAMICS
The Castration-Resistant Prostate Cancer/HRPCA Therapeutics market is anticipated to grow in the forecast period owing to driving factors such as large amount of drugs in pipeline, augmented patient awareness and untapped nmCRPC space. Nevertheless, lack of action mechanism among the approved treatments is expected to restrict the growth of the market during the forecast period.

MARKET SCOPE
The "Global Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Castration-Resistant Prostate Cancer/HRPCA Therapeutics market with detailed market segmentation by Therapy, Drug Delivery and geography. The global Castration-Resistant Prostate Cancer/HRPCA Therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Castration-Resistant Prostate Cancer/HRPCA Therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Castration-Resistant Prostate Cancer/HRPCA Therapeutics market is segmented on the basis of Therapy and Drug Delivery. Based on Therapy the market is segmented into Hormonal Therapy, Chemotherapy, Immunotherapy, and Radiotherapy. Based on Drug Delivery the market is segmented into Oral, Injectable.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Castration-Resistant Prostate Cancer/HRPCA Therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Castration-Resistant Prostate Cancer/HRPCA Therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Castration-Resistant Prostate Cancer/HRPCA Therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Castration-Resistant Prostate Cancer/HRPCA Therapeutics market in these regions.

MARKET PLAYERS
The reports cover key developments in the Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market are anticipated to lucrative growth opportunities in the future with the rising demand for Castration-Resistant Prostate Cancer/HRPCA Therapeutics in the global market. Below mentioned is the list of few companies engaged in the Castration-Resistant Prostate Cancer/HRPCA Therapeutics market.

The report also includes the profiles of key Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Johnson & Johnson
  • Dendreon Corporation
  • Sanofi
  • Bayer
  • Astellas Pharma Inc
  • Novartis
  • National Cancer Institute
  • Pfizer
  • Merck Sharp & Dohme Corp
  • AstraZeneca
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market - By Therapy
1.3.2 Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market - By Drug Delivery
1.3.3 Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY
7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. HORMONAL THERAPY
7.3.1. Overview
7.3.2. Hormonal Therapy Market Forecast and Analysis
7.4. CHEMOTHERAPY
7.4.1. Overview
7.4.2. Chemotherapy Market Forecast and Analysis
7.5. IMMUNOTHERAPY
7.5.1. Overview
7.5.2. Immunotherapy Market Forecast and Analysis
7.6. RADIOTHERAPY
7.6.1. Overview
7.6.2. Radiotherapy Market Forecast and Analysis
8. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG DELIVERY
8.1. OVERVIEW
8.2. DRUG DELIVERY MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. INJECTABLE.
8.4.1. Overview
8.4.2. Injectable. Market Forecast and Analysis
9. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Overview
9.1.2 North America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis
9.1.3 North America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Therapy
9.1.4 North America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Drug Delivery
9.1.5 North America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.1.5.1.1 United States Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.1.5.1.2 United States Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.1.5.2 Canada Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.1.5.2.1 Canada Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.1.5.2.2 Canada Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.1.5.3 Mexico Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.1.5.3.1 Mexico Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.1.5.3.2 Mexico Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.1.5.4 US Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.1.5.4.1 US Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.1.5.4.2 US Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.2. EUROPE
9.2.1 Europe Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Overview
9.2.2 Europe Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis
9.2.3 Europe Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Therapy
9.2.4 Europe Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Drug Delivery
9.2.5 Europe Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.2.5.1.1 Germany Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.2.5.1.2 Germany Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.2.5.2 France Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.2.5.2.1 France Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.2.5.2.2 France Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.2.5.3 Italy Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.2.5.3.1 Italy Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.2.5.3.2 Italy Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.2.5.4 Spain Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.2.5.4.1 Spain Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.2.5.4.2 Spain Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.2.5.5 United Kingdom Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.2.5.5.1 United Kingdom Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.2.5.5.2 United Kingdom Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Overview
9.3.2 Asia-Pacific Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Therapy
9.3.4 Asia-Pacific Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Drug Delivery
9.3.5 Asia-Pacific Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.3.5.1.1 Australia Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.3.5.1.2 Australia Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.3.5.2 China Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.3.5.2.1 China Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.3.5.2.2 China Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.3.5.3 India Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.3.5.3.1 India Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.3.5.3.2 India Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.3.5.4 Japan Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.3.5.4.1 Japan Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.3.5.4.2 Japan Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Overview
9.4.2 Middle East and Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Therapy
9.4.4 Middle East and Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Drug Delivery
9.4.5 Middle East and Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.4.5.1.1 South Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.4.5.1.2 South Africa Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.4.5.2 Saudi Arabia Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.4.5.2.1 Saudi Arabia Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.4.5.2.2 Saudi Arabia Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.4.5.3 U.A.E Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.4.5.3.1 U.A.E Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.4.5.3.2 U.A.E Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Overview
9.5.2 South and Central America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Therapy
9.5.4 South and Central America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Drug Delivery
9.5.5 South and Central America Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.5.5.1.1 Brazil Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.5.5.1.2 Brazil Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
9.5.5.2 Argentina Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market
9.5.5.2.1 Argentina Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Therapy
9.5.5.2.2 Argentina Castration-Resistant Prostate Cancer/HRPCA Therapeutics Market by Drug Delivery
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CASTRATION-RESISTANT PROSTATE CANCER/HRPCA THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. JOHNSON AND JOHNSON
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. DENDREON CORPORATION
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. SANOFI
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BAYER
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ASTELLAS PHARMA INC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. NOVARTIS
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NATIONAL CANCER INSTITUTE
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. MERCK SHARP AND DOHME CORP
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. ASTRAZENECA
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

- Johnson & Johnson
- Dendreon Corporation
- Sanofi
- Bayer
- Astellas Pharma Inc
- Novartis
- National Cancer Institute
- Pfizer
- Merck Sharp & Dohme Corp
- AstraZeneca
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book